Study Summary
This clinical study is to investigate the safety and tolerability of CAR modified autologous T cells (CCT301-59) in subjects with recurrent or refractory solid tumors.
Want to learn more about this trial?
Request More InfoInterventions
CCT301-59BIOLOGICAL
Collect blood from the patients and isolate peripheral blood mononuclear cells for the production of CCT301-59. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion during the production of CCT301-59 and then subjects will receive one dose of CCT301-59 via intravenous injection.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Shanghai Zhongshan Hospital | Shanghai | Shanghai Municipality | China |